Ellume expands recall of rapid at-home COVID-19 tests

Nov 12, 2021 - 11:01 AM
fda-alert-recall-compounded-drugs

Ellume has expanded its recall of rapid at-home COVID-19 antigen tests to about 2 million tests, the Food and Drug Administration said in an update this week. Ellume last month recalled certain lots of its COVID-19 Home Test due to an increased chance of false-positive results. FDA has classified the recall as a Class I recall, the most serious type.

“The FDA is continuing to work with Ellume to assess the company’s corrective actions, such as additional manufacturing checks and other corrective steps, to address the reason for the manufacturing issue, and to help ensure that it is resolved and will not recur,” the agency said.

 

Related News Articles

Headline
CDC encourages older adults to get additional COVID-19 vaccine dose 
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
FDA: Paxlovid no longer labeled for emergency use after March 8
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
FDA evaluating certain plastic syringes made in China
The Food and Drug Administration is evaluating Chinese-made plastic syringes used to inject or withdraw fluids from the body, citing concern that they may…
Headline
FDA advisor declares ineffectiveness of widely used over-the-counter decongestant active ingredient
The Food and Drug Administration’s independent Nonprescription Drugs Advisory Committee Sept. 12 by unanimous vote declared oral phenylephrine…
Headline
FDA announces Class I ventilator recall for Draeger product’s pediatric use
Draeger Medical, Inc. is recalling its Carina Ventilators due to the presence of contaminants in the device’s airpath, which exceed acceptable levels if…
Headline
Pfizer issues update on sterile injectables plant struck by tornado
Crews are working to restore power and assess damage to a Pfizer plant in North Carolina that makes sterile injectables for U.S. hospitals after a tornado…